Neurizon

Neurizon Therapeutics Limited (ASX: NUZ) (formerly PharmAust) is a clinical-stage biotechnology company dedicated to advancing treatments for neurodegenerative diseases. Neurizon is developing its lead candidate drug, NUZ-001, for the treatment of amyotrophic lateral sclerosis (ALS), the most common motor neuron disease. Neurizon’s strategy is to accelerate patient access to effective ALS therapies while exploring the broader potential of NUZ-001 in treating a wider range of neurodegenerative conditions. Through international collaboration and rigorous clinical programs, Neurizon is committed to pioneering new therapeutic prospects for patients and families affected by complex neurological disorders.